Results 1 to 10 of about 10,862 (118)

Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review

Thoracic Cancer, 2020
Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, in EU countries, nintedanib plus docetaxel is used for patients with advanced non‐small cell lung cancer (NSCLC) after first‐line chemotherapy.
Chiori Tabe, Masamichi Itoga, Hisashi Tanaka   +2 more
exaly   +2 more sources

Nintedanib induces apoptosis in human pterygium cells through the FGFR2-ERK signalling pathway [PDF]

International Journal of Ophthalmology, 2023
AIM: To investigate whether nintedanib can inhibit pterygium cells through the fibroblast growth factor receptor 2 (FGFR2)/extracellular-signal-regulated kinase (ERK) pathway. METHODS: Human primary pterygium cells were cultured in vitro. After treatment
Yan Gong, Yan-Hong Liao, Quan-Yong Yi, Meng Li, Li-Shuang Chen, Yan-Yan Wang   +5 more
doaj   +1 more source

Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis–associated interstitial lung disease mice

PLoS ONE, 2022
Nintedanib is a multi-tyrosine kinase inhibitor widely used to treat progressive fibrosing interstitial lung diseases because it slows the reduction in forced vital capacity. However, the prognosis for patients treated with nintedanib remains poor.
Shintaro Mikami, Yoko Miura, Shinji Kondo, Kosuke Sakai, Hiroaki Nishimura, Hiroyuki Kyoyama, Gaku Moriyama, Nobuyuki Koyama, Hideki Noguchi, Hirotsugu Ohkubo, Satoshi Kanazawa, Kazutsugu Uematsu   +11 more
doaj   +2 more sources

Evaluation of nintedanib as a new postoperative antiscarring agent in experimental extraocular muscle surgery [PDF]

International Journal of Ophthalmology, 2022
AIM: To investigate the efficacy of nintedanib on reducing postoperative inflammation, fibrosis and adhesion formation following extraocular muscle surgery in rabbits in comparison with triamcinolone acetonide (TA).
Gozde Bicaklioglu, Dilara Pirhan, Yusufhan Yazir, Gokhan Duruksu, Selenay Furat Rencber, Nursen Yuksel   +5 more
doaj   +1 more source

Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity

Frontiers in Oncology, 2023
Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors.
Shu Yan, Shuyu Xue, Tiantian Wang, Ruihang Gao, Hanqiao Zeng, Qianmeng Wang, Xiaojing Jia   +6 more
doaj   +1 more source

Delayed Administration of Nintedanib Ameliorates Fibrosis Progression in CG-Induced Peritoneal Fibrosis Mouse Model

Kidney Diseases, 2022
Background: A multiple-target tyrosine kinase inhibitor, nintedanib, which is approved for treatment of interstitial pulmonary disease, has been demonstrated to have anti-fibrotic activity outside of the lungs.
Binbin Cui, Chao Yu, Shenglei Zhang, Xiying Hou, Yi Wang, Jun Wang, Shougang Zhuang, Feng Liu   +7 more
doaj   +1 more source

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study

Biomedicines, 2022
Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subjects ...
Paolo Cameli, Valerio Alonzi, Miriana d’Alessandro, Laura Bergantini, Elena Pordon, Marco Guerrieri, Rosa Metella Refini, Piersante Sestini, Elena Bargagli   +8 more
doaj   +1 more source

Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis

Medicina, 2023
Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. The most common side effect of Nintedanib is diarrhea, and thrombocytopenia is a rare side effect of Nintedanib.
Igor Dumic, Antonios Charokopos, Angadabir Parmar, Christopher R. Grant, Ronin Joshua S. Cosiquien, Marilia Dagnon da Silva, Emilia Petcu   +6 more
doaj   +1 more source

Nintedanib induces senolytic effect via STAT3 inhibition

Cell Death and Disease, 2022
Selective removal of senescent cells, or senolytic therapy, has been proposed to be a potent strategy for overcoming age-related diseases and even for reversing aging.
Hyun-Ji Cho, Jeong-A Hwang, Eun Jae Yang, Eok-Cheon Kim, Jae-Ryong Kim, Sung Young Kim, Young Zoon Kim, Sang Chul Park, Young-Sam Lee   +8 more
doaj   +1 more source

Galectin-3 levels are elevated following nintedanib treatment

Therapeutic Advances in Chronic Disease, 2020
Background and Aims: Idiopathic pulmonary fibrosis (IPF) is a common and severe form of pulmonary fibrosis. Nintedanib, a triple angiokinase inhibitor, is approved for treating IPF.
Gali Epstein Shochet, Alon Pomerantz, David Shitrit, Becky Bardenstein-Wald, Kjetil Ask, Mark Surber, Noa Rabinowicz, Yair Levy, Sydney Benchetrit, Evgeny Edelstein, Tali Zitman-Gal   +10 more
doaj   +1 more source